bit.bio: Funding, Investors & Team (Sep 2026)
Bit.bio specializes in the fields of coding and biology that determine the identity of every human cell. Their mission is coding cells for health. To do so, we apply the principles of computation to biology. Bit.bio's current focus is to develop a scalable technology platform capable of producing consistent batches of every human cell. This has the potential to unlock a new generation of medicine: it will enable research and drug discovery to move on from inappropriate models and work with the cells that actually are affected by the human disease. A scalable platform of consistent cells will also be the basis for a new generation of cell and tissue therapies. To achieve our goals, we have assembled a team of pioneers in stem cells, cellular reprogramming, mathematical modeling, and cell therapy. Collaboration is at the heart of bit.bio. We are empirical, highly ambitious, and driven by a common purpose.
bit.bio has raised $195M across 4 funding rounds on record, the most recent a Series C of $50.0M announced in Jan 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
bit.bio Company Profile and Key Stats
Latest funding round on record: Jan 2026.
bit.bio Funding Rounds
1 of 4 rounds was announced without a disclosed amount and is excluded from the total.
bit.bio raised $41.5M in an undisclosed round announced in Jun 2020.
1.4 years later, a Series B of $103M was announced in Nov 2021.
2.5 years later, an undisclosed round was announced in May 2024 with no disclosed amount.
1.7 years later, a Series C of $50.0M was announced in Jan 2026.
bit.bio Founders and Leadership Team
Contact details for the bit.bio team: 1 of 2 have an email address on file.
Start 14-day free trial →bit.bio Funding Compared to Other Biotechnology Startups
bit.bio's latest round of $50.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like bit.bio in Biotechnology and Cambridge
Companies Similar to bit.bio
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
IMU is a discovery engine mapping the immune system to advance precision medicine.
Mykor is a climate tech start-up. It decarbonizes the construction industry by manufacturing carbon-negative…
Neurovalens provides cutting-edge solutions in the realms of neuroscience, bioscience, and neurophysiology.…
Voxmind's biometric confirmation and authentication platform that provides voice based biometrics that helps…
Five is a biometric payment services company that offers thumb recognition technology for safe transactions.
bit.bio Funding FAQs
What does bit.bio do?
Bit.bio specializes in the fields of coding and biology that determine the identity of every human cell. Their mission is coding cells for health. To do so, we apply the principles of computation to biology. Bit.bio's current focus is to develop a scalable technology platform capable of producing consistent batches of every human cell. This has the potential to unlock a new generation of medicine: it will enable research and drug discovery to move on from inappropriate models and work with the cells that actually are affected by the human disease. A scalable platform of consistent cells will also be the basis for a new generation of cell and tissue therapies. To achieve our goals, we have assembled a team of pioneers in stem cells, cellular reprogramming, mathematical modeling, and cell therapy. Collaboration is at the heart of bit.bio. We are empirical, highly ambitious, and driven by a common purpose.
How much funding has bit.bio raised?
bit.bio has raised $195M across 4 rounds on record. The most recent is a Series C of $50.0M announced in Jan 2026.
When did bit.bio last raise funding?
bit.bio's most recent funding round on record is a Series C of $50.0M, announced in Jan 2026.
Who founded bit.bio?
FundedIQ lists Florian Schuster (Founder) at bit.bio.
Who is the CEO of bit.bio?
Mark Kotter is listed as CEO at bit.bio.
Where is bit.bio headquartered?
bit.bio is based in Cambridge, Cambridgeshire, United Kingdom.
How many employees does bit.bio have?
bit.bio is in the 101-250 employee band.
How does bit.bio's funding compare to other Biotechnology startups?
bit.bio's latest round of $50.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's bit.bio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for bit.bio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.